Novocure (NASDAQ: NVCR) reported Q1 EPS of ($0.23), $0.10 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $52.13 million versus the consensus estimate of $56.65 million.

• 2,009 active patients at March 31, 2018, an increase of 59 percent versus March 31, 2017
• Delivered quarterly net revenues of $52.1 million, representing 49 percent growth versus the first quarter 2017
• NCCN guidelines updated to recommend Optune in combination with temozolomide as a category 1 treatment for newly diagnosed glioblastoma
• Positive topline results from STELLAR trial in mesothelioma exceeded the results of the interim analysis for all efficacy endpoints

For earnings history and earnings-related data on Novocure (NVCR) click here.